Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Uncontrolled, Open-label Study to Evaluate the Safety and Tolerability of Intravenous Perampanel as Substitute for Oral Tablet in Subjects With Partial Onset Seizures (Including Secondarily Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

NCT03754582 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT03754582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03754582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Uncontrolled, Open-label Study to Evaluate the Safety and Tolerability of Intravenous Perampanel as Substitute for Oral Tablet in Subjects With Partial Onset Seizures (Including Secondarily Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
Lead sponsor
Eisai Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
November 27, 2018
Completion date
December 10, 2019
Enrollment
21 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy, seizures